Manufacturing & Operations

Jason Mieding Appointed MedPharm’s First Chief Operating Officer

By TPN Editorial TeamNovember 16, 2026
Jason Mieding Appointed MedPharm’s First Chief Operating Officer
Sign in to save article

The former Thermo Fisher and Patheon executive will lead MedPharm’s Durham manufacturing site and oversee operational strategy as the topical and transdermal CDMO invests in expanded capabilities.

Sanner

MedPharm has announced the creation of a Chief Operating Officer (COO) role and appointed pharmaceutical manufacturing veteran Jason Mieding to the position (1). Mieding will lead the company’s 110,000 sq. ft. semi-solid manufacturing facility in Durham, North Carolina, U.S., as MedPharm expands its production capacity and operations.

Mieding joins the topical and transdermal CDMO after holding increasingly senior roles at Thermo Fisher Scientific and Patheon. He brings experience in pharmaceutical manufacturing and operations, which MedPharm says will support its growth and investment in new capabilities.

As COO and site head, Mieding will be responsible for running the Durham semi-solid manufacturing facility, including operational strategy, execution, and performance. He will also contribute to strategic planning, capital allocation, organizational development, and company culture.

“I’m excited to be joining MedPharm at such an important time in the company’s history,” Mieding said in a company press release about his appointment (1). “The company has a strong reputation for its expertise and commitment to operational excellence, and I look forward to working with the team to build on this foundation, drive continuous improvement, delight our customers, and support the company’s continued growth.”

MedPharm Chief Executive Bill Humphries said Mieding’s background in commercial pharmaceutical manufacturing and operational excellence would be a “real asset” as the company’s growth accelerates. “His leadership will be important in supporting our team and ensuring we continue to deliver for our customers,” Humphries added in the press release (1).

The appointment comes as MedPharm continues to expand following its 2024 merger with Durham-based Tergus Pharma (2). The combination brought together formulation development, in vitro testing, clinical manufacturing, and large-scale commercial production under the MedPharm name.

MedPharm specializes in topical and transepithelial medicines, including dermal, transdermal, lung and nasal, mucosal, ungual, otic, and ophthalmic delivery systems. The company operates in the UK and U.S., with its Durham site providing CGMP clinical and commercial manufacturing for semi-solid dosage forms.

The newly created COO role reflects the organization’s growth over the past 22 months, MedPharm reported. Mieding’s appointment is intended to strengthen the leadership team as the company invests in manufacturing capacity and seeks to meet rising demand from pharmaceutical clients.

MedPharm said the move reinforces its focus on operational excellence and customer delivery as it develops and manufactures complex topical and transdermal products. The company has more than 25 years of experience in reducing development risk through its in vitro testing and research biology models.

References

1. MedPharm. MedPharm Strengthens Executive Leadership Team with Appointment of Jason Mieding as Chief Operating Officer. Press Release, Nov. 5, 2026.
2. The Pharma Navigator. MedPharm and Tergus Pharma Merge to Form Topical & Transepithelial CDMO. thepharmanavigator.com, accessed Nov. 12, 2026.

Sanner